Remissions After Long-term Use of Romiplostim for Immune Thrombocytopenia

Overview

Journal Haematologica

Specialty Hematology

Date 2016 Sep 3

PMID 27587382

Citations 6

Authors

Ariela L Marshall

Roberta Scarpone

Melanie De Greef

Robert Bird

David J Kuter

Affiliations

Soon will be listed here.

Citing Articles

Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey.

Kaushansky K Biomolecules. 2024; 14(4).

PMID: 38672505 PMC: 11047867. DOI: 10.3390/biom14040489.

Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia.

Goshua G, Sinha P, Kunst N, Pischel L, Lee A, Cuker A Am J Hematol. 2022; 98(1):122-130.

PMID: 35147241 PMC: 9365880. DOI: 10.1002/ajh.26497.

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.

Carpenedo M, Baldacci E, Barate C, Borchiellini A, Buccisano F, Calvaruso G Ther Adv Hematol. 2021; 12:20406207211048361.

PMID: 34646432 PMC: 8504223. DOI: 10.1177/20406207211048361.

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.

Cuker A, Despotovic J, Grace R, Kruse C, Lambert M, Liebman H Res Pract Thromb Haemost. 2021; 5(1):69-80.

PMID: 33537531 PMC: 7845076. DOI: 10.1002/rth2.12457.

Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Provan D, Arnold D, Bussel J, Chong B, Cooper N, Gernsheimer T Blood Adv. 2019; 3(22):3780-3817.

PMID: 31770441 PMC: 6880896. DOI: 10.1182/bloodadvances.2019000812.

References

Nugent D, McMillan R, Nichol J, Slichter S . Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009; 146(6):585-96. DOI: 10.1111/j.1365-2141.2009.07717.x. View

Kaushansky K . Thrombopoietin: the primary regulator of platelet production. Blood. 1995; 86(2):419-31. View

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2008; 113(11):2386-93. DOI: 10.1182/blood-2008-07-162503. View

Gonzalez-Lopez T, Pascual C, Alvarez-Roman M, Fernandez-Fuertes F, Sanchez-Gonzalez B, Caparros I . Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2014; 90(3):E40-3. DOI: 10.1002/ajh.23900. View

Bussel J, Kuter D, George J, McMillan R, Aledort L, Conklin G . AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006; 355(16):1672-81. DOI: 10.1056/NEJMoa054626. View

Cines D, Blanchette V . Immune thrombocytopenic purpura. N Engl J Med. 2002; 346(13):995-1008. DOI: 10.1056/NEJMra010501. View

Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther M . The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16):4190-207. DOI: 10.1182/blood-2010-08-302984. View

Carpenedo M, Cantoni S, Coccini V, Fedele M, Morra E, Pogliani E . Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice. Hematol Rep. 2015; 7(1):5673. PMC: 4378205. DOI: 10.4081/hr.2015.5673. View

Newland A, Godeau B, Priego V, Viallard J, Lopez Fernandez M, Orejudos A . Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2015; 172(2):262-73. DOI: 10.1111/bjh.13827. View

10.

Kuter D, Bussel J, Lyons R, Pullarkat V, Gernsheimer T, Senecal F . Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371(9610):395-403. DOI: 10.1016/S0140-6736(08)60203-2. View

11.

Kuter D, Bussel J, Newland A, Baker R, Lyons R, Wasser J . Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013; 161(3):411-23. DOI: 10.1111/bjh.12260. View

12.

Mahevas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M . The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014; 165(6):865-9. DOI: 10.1111/bjh.12888. View

13.

Ghanima W, Junker P, Hasselbalch H, Boiocchi L, Geyer J, Feng X . Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol. 2011; 155(2):248-55. DOI: 10.1111/j.1365-2141.2011.08845.x. View

14.

George J, Woolf S, Raskob G, Wasser J, Aledort L, Ballem P . Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88(1):3-40. View

15.

Bussel J, Kuter D, Pullarkat V, Lyons R, Guo M, Nichol J . Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2008; 113(10):2161-71. DOI: 10.1182/blood-2008-04-150078. View